Stock listing
NASDAQ:NEUP Neuphoria Therapeutics Inc. Stock
Home listing (NASDAQ) of Neuphoria Therapeutics Inc.
Follow Neuphoria Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NEUP
$2.35 USD +0.07 (+3.1%)
Close on Nov 20, 2026
- Day range
- $2.27 – $2.38 USDNov 20, 2026
- Volume
- 55,960 sharesNov 20, 2026
- Market cap
- $12.72M USDAt the close on Nov 20, 2026 · price × 5.41M shares outstanding
- 52-week range
- $2.26 – $5.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $98,365 USDMedian day 20,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NEUP · Home | $2.35 USD | +0.07 (+3.1%) | 55,960 | $2.33 | $2.38 | $2.27 | $2.28 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NEUP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.35 | +0.07 | +3.1% | $2.33 | $2.38 | $2.27 | 55,960 | |
| $2.28 | +0.01 | +0.4% | $2.27 | $2.405 | $2.27 | 24,224 | |
| $2.27 | -0.21 | -8.5% | $2.51 | $2.51 | $2.26 | 33,724 | |
| $2.48 | -0.07 | -2.7% | $2.47 | $2.54 | $2.45 | 23,377 | |
| $2.55 | -0.03 | -1.2% | $2.63 | $2.635 | $2.49 | 14,971 | |
| $2.58 | -0.13 | -4.8% | $2.67 | $2.765 | $2.54 | 19,500 | |
| $2.71 | +0.02 | +0.7% | $2.675 | $2.755 | $2.67 | 34,713 | |
| $2.69 | -0.07 | -2.5% | $2.795 | $2.81 | $2.62 | 28,870 | |
| $2.76 | -0.02 | -0.7% | $2.86 | $2.86 | $2.75 | 23,995 | |
| $2.78 | +0.01 | +0.4% | $2.732 | $2.83 | $2.732 | 19,631 | |
| $2.77 | -0.21 | -7.0% | $2.97 | $2.975 | $2.71 | 40,020 | |
| $2.98 | -0.01 | -0.3% | $3.05 | $3.07 | $2.98 | 77,554 | |
| $2.99 | -0.05 | -1.6% | $3.05 | $3.05 | $2.99 | 7,828 | |
| $3.04 | -0.01 | -0.3% | $3.10 | $3.10 | $2.99 | 52,454 | |
| $3.05 | -0.01 | -0.3% | $3.10 | $3.11 | $3.04 | 70,249 | |
| $3.06 | -0.30 | -8.9% | $3.32 | $3.32 | $3.032 | 70,085 | |
| $3.36 | -0.03 | -0.9% | $3.40 | $3.42 | $3.32 | 16,063 | |
| $3.39 | +0.01 | +0.3% | $3.38 | $3.39 | $3.38 | 3,638 | |
| $3.38 | -0.06 | -1.7% | $3.39 | $3.46 | $3.355 | 26,699 | |
| $3.44 | -0.04 | -1.1% | $3.46 | $3.59 | $3.37 | 73,000 | |
| $3.48 | 0.00 | 0.0% | $3.46 | $3.56 | $3.46 | 4,800 | |
| $3.48 | +0.09 | +2.7% | $3.49 | $3.54 | $3.465 | 8,800 | |
| $3.39 | +0.08 | +2.4% | $3.365 | $3.40 | $3.33 | 20,800 | |
| $3.31 | +0.01 | +0.3% | $3.24 | $3.41 | $3.24 | 39,500 | |
| $3.30 | -0.01 | -0.3% | $3.35 | $3.41 | $3.24 | 76,000 | |
| $3.31 | +0.07 | +2.2% | $3.25 | $3.42 | $3.25 | 18,700 | |
| $3.24 | -0.15 | -4.4% | $3.32 | $3.37 | $3.24 | 44,100 | |
| $3.39 | +0.07 | +2.1% | $3.49 | $3.49 | $3.32 | 26,600 | |
| $3.32 | -0.04 | -1.2% | $3.32 | $3.38 | $3.32 | 10,000 | |
| $3.36 | +0.01 | +0.3% | $3.33 | $3.41 | $3.32 | 2,500 | |
| $3.35 | -0.07 | -2.0% | $3.40 | $3.42 | $3.34 | 16,500 | |
| $3.42 | -0.03 | -0.9% | $3.40 | $3.45 | $3.40 | 4,500 | |
| $3.45 | 0.00 | 0.0% | $3.45 | $3.50 | $3.43 | 16,500 | |
| $3.45 | -0.02 | -0.6% | $3.45 | $3.50 | $3.43 | 15,500 | |
| $3.47 | -0.04 | -1.1% | $3.51 | $3.59 | $3.45 | 12,600 | |
| $3.51 | -0.05 | -1.4% | $3.525 | $3.54 | $3.50 | 14,300 | |
| $3.56 | -0.01 | -0.3% | $3.60 | $3.615 | $3.53 | 10,400 | |
| $3.57 | -0.08 | -2.2% | $3.64 | $3.65 | $3.57 | 15,000 | |
| $3.65 | 0.00 | 0.0% | $3.67 | $3.69 | $3.65 | 2,900 | |
| $3.65 | 0.00 | 0.0% | $3.67 | $3.67 | $3.65 | 1,300 | |
| $3.65 | -0.03 | -0.8% | $3.67 | $3.70 | $3.65 | 5,400 | |
| $3.68 | -0.055 | -1.5% | $3.69 | $3.755 | $3.66 | 15,500 | |
| $3.735 | +0.025 | +0.7% | $3.73 | $3.77 | $3.71 | 6,700 | |
| $3.71 | +0.01 | +0.3% | $3.69 | $3.79 | $3.68 | 17,900 | |
| $3.70 | -0.015 | -0.4% | $3.712 | $3.83 | $3.70 | 21,600 | |
| $3.715 | -0.025 | -0.7% | $3.79 | $3.79 | $3.71 | 5,300 | |
| $3.74 | -0.04 | -1.1% | $3.72 | $3.81 | $3.72 | 36,800 | |
| $3.78 | -0.02 | -0.5% | $3.75 | $3.80 | $3.73 | 17,700 | |
| $3.80 | +0.07 | +1.9% | $3.78 | $3.84 | $3.74 | 12,400 | |
| $3.73 | 0.00 | 0.0% | $3.78 | $3.78 | $3.72 | 23,000 | |
| $3.73 | -0.02 | -0.5% | $3.79 | $3.793 | $3.70 | 43,000 | |
| $3.75 | 0.00 | 0.0% | $3.795 | $3.865 | $3.75 | 18,600 | |
| $3.75 | -0.02 | -0.5% | $3.84 | $3.84 | $3.72 | 22,600 | |
| $3.77 | +0.01 | +0.3% | $3.74 | $3.78 | $3.73 | 21,900 | |
| $3.76 | +0.01 | +0.3% | $3.84 | $3.84 | $3.742 | 7,300 | |
| $3.75 | -0.04 | -1.1% | $3.84 | $3.84 | $3.75 | 17,900 | |
| $3.79 | +0.03 | +0.8% | $3.73 | $3.81 | $3.73 | 20,800 | |
| $3.76 | 0.00 | 0.0% | $3.71 | $3.815 | $3.71 | 52,200 | |
| $3.76 | -0.01 | -0.3% | $3.72 | $3.835 | $3.72 | 29,900 | |
| $3.77 | -0.09 | -2.3% | $3.84 | $3.90 | $3.71 | 50,100 | |
| $3.86 | 0.00 | 0.0% | $3.86 | $3.995 | $3.854 | 41,000 | |
| $3.86 | -0.09 | -2.3% | $3.93 | $3.96 | $3.85 | 33,600 | |
| $3.95 | +0.04 | +1.0% | $3.90 | $4.01 | $3.90 | 57,900 | |
| $3.91 | -0.04 | -1.0% | $3.98 | $4.05 | $3.91 | 179,800 | |
| $3.95 | +0.02 | +0.5% | $3.98 | $4.00 | $3.92 | 55,700 |
Splits
1 split · NASDAQ:NEUP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:NEUP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Jul 23, 2026
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Latest deck · Jul 24, 2026
Investor Presentation (July 2026)
Investor deck · 35 slides
Latest news
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Jul 23, 2026
Closed $3.92 (+17.7%) on Jul 23, 2026
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Jun 26, 2026
Closed $4.40 (-3.7%) on Jun 29, 2026
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
Dec 8, 2025
Closed $4.54 (+6.3%) on Dec 8, 2025
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
Dec 4, 2025
Closed $4.27 (+1.9%) on Dec 4, 2025
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Dec 2, 2025
Closed $4.19 (-4.1%) on Dec 3, 2025
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Dec 1, 2025
Closed $4.39 (-2.9%) on Dec 1, 2025
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Nov 24, 2025
Closed $4.43 (-0.7%) on Nov 24, 2025
Neuphoria Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 78 in all · newest Jul 23, 2026 · oldest 2021
- Decks
- 5 decks · latest Jul 24, 2026
Where Neuphoria Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NEUP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NEUP | BOATS | United States | USD |
Valuation
Price/book 0.5× against a median of 1.5×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$6.03M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.61
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. · NASDAQ:NEUP | US$12.72M | −US$6.03M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.61 |
| Tvardi Therapeutics, Inc. · NASDAQ:TVRD | US$13.22M | −US$9.05M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.89 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.22M | −US$16.66M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Bolt Biotherapeutics, Inc. · NASDAQ:BOLT | US$12.80M | US$18.89M | n/a | 7.5× | n/a | 1.5× | n/a | 2.4× | 0.52 |
| Avai Bio, Inc. · OTC:AVAI | US$12.79M | US$12.67M | n/a | n/a | n/a | n/a | n/a | n/a | 0.28 |
| Seres Therapeutics, Inc. · NASDAQ:MCRB | US$12.64M | US$30.89M | n/a | 14.5× | n/a | 0.6× | n/a | 1.7× | 1.21 |
| Passage Bio, Inc. · NASDAQ:PASG | US$12.61M | −US$7.55M | n/a | n/a | n/a | 252× | n/a | 0.0× | 1.94 |
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$12.72M | US$12.63M | 7.5× | 1.5× | −204.1% | 0.0× | 0.87 |
Forecasts
1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.00 USD · Analysts' mean
- EPS, year to Jun 2027
- -2.43 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Spyros Papapetropoulos | Interim CEO & Executive Director |
| Tim Cunningham | Fractional CFO |
| Spyridon Papapetropoulos | IR & PR |
Board
| Director | Role |
|---|---|
| Alan Fisher | Non-Executive Chairman |
| David Wilson | Non-Executive Director |
| Jane Ryan | Non-Executive Director |
| Miles Davies | Non-Executive Director |
| Spyros Papapetropoulos | Interim CEO & Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 16, 2026 | −11.0% |
| Q4 2026 | Sep 18, 2026 · After close | +0.3% |
| Q3 2026 | May 15, 2026 · Before open | −7.1% |
| Q2 2026 | Feb 17, 2026 · After close | +8.9% |
| Q1 2026 | Nov 14, 2025 | −1.1% |
| Q4 2025 | Sep 29, 2025 · After close | −0.6% |
| Q3 2025 | May 20, 2025 · After close | +2.4% |
| Q2 2025 | Feb 20, 2025 | −6.7% |
| Q1 2025 | Nov 27, 2024 | +6.0% |
| Q4 2024 | Aug 21, 2024 | −2.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 29, 2024 | +1.3% |
| Q2 2024 | Feb 22, 2024 | −8.8% |
| Q1 2024 | Nov 29, 2023 | −9.0% |
| Q4 2023 | Aug 23, 2023 | +25.0% |
| Q3 2023 | May 31, 2023 | +0.9% |
| Q2 2023 | Feb 23, 2023 | +30.3% |
| Q1 2023 | Nov 30, 2022 | +0.1% |
| Q4 2022 | Aug 25, 2022 | +0.3% |
| Q3 2022 | Jun 1, 2022 | 0.0% |
| Q2 2022 | Feb 23, 2022 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 35 slides | Jul 24, 2026 |
| Proxy Contest (November 2025) | Proxy contest | 18 slides | Nov 26, 2025 |
| Proxy Contest (November 2025) | Proxy contest | 25 slides | Nov 25, 2025 |
| Investor Presentation (2025) | Investor deck | 40 slides | 2025 |
| Bionomics — H.C. Wainwright BIOCONNECT Virtual Conference 2022 | Conference | 37 slides | Jan 12, 2022 |
IPO
Went public as BIONOMICS LIMITED/FI. Priced at US$12.35 an ADS on Dec 15, 2021.
- Price
- US$12.35 an ADS
- ADSs offered
- 1,622,000 American depositary shares
- Offering size
- US$20 million
- Underwriters
- Evercore ISI, William Blair, Cantor, Berenberg, H.C. Wainwright & Co. · In the order on the cover
- ADSs delivered
- On or about Dec 20, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 10, 2021 |
| Filed publicly | Nov 22, 2021 |
| Amended twice | Newest Dec 13, 2021 |
| Shares registered with an exchange | Dec 13, 2021 |
| Declared effective by the SEC | Dec 15, 2021 |
| Final prospectus, with the price | Dec 17, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 17, 2021 |
| EFFECT · Notice that a registration is effective | Dec 15, 2021 |
| CORRESP · Letter to the SEC | Dec 15, 2021 |
| CORRESP · Letter to the SEC | Dec 15, 2021 |
| CERT · Exchange's certificate of listing | Dec 14, 2021 |
| CORRESP · Letter to the SEC | Dec 13, 2021 |
| CORRESP · Letter to the SEC | Dec 13, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 13, 2021 |
| F-1/A · Registration statement, amended | Dec 13, 2021 |
| CORRESP · Letter to the SEC | Dec 8, 2021 |
All 19 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Dec 8, 2021 |
| UPLOAD · Letter from the SEC | Dec 3, 2021 |
| CORRESP · Letter to the SEC | Nov 22, 2021 |
| F-1 · Registration statement | Nov 22, 2021 |
| UPLOAD · Letter from the SEC | Nov 12, 2021 |
| DRS/A · Draft registration statement, amended | Oct 28, 2021 |
| DRSLTR · Letter to the SEC with a draft | Oct 27, 2021 |
| UPLOAD · Letter from the SEC | Oct 8, 2021 |
| DRS · Draft registration statement | Sep 10, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2021
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17M | 15.6M | 0 | 0 | 383.2K | 927.5K | 32.1K | 7.40M | 11.9M | 27.1M |
| Cost of revenue | 663.0K | 662.9K | 663.0K | 671.5K | 16.0M | 1.69M | 12.1M | 25.4M | 24.2M | |
| Gross profit | 1.17M | 15.6M | -663.0K | -671.5K | -9.98M | -1.27M | 32.1K | 2.68M | -13.4M | 2.84M |
| Research and development | 3.55M | 9.01M | 9.42M | 13.1M | 23.3M | 4.33M | 4.00M | 6.29M | 18.5M | 18.6M |
| Selling, general and administrative | 7.44M | 7.77M | 8.47M | 13.4M | 7.43M | 4.24M | 3.33M | 6.55M | 4.97M | 5.72M |
| Operating income | -16.5M | -1.13M | -17.9M | -22.0M | -31.0M | -8.96M | -6.19M | -10.8M | -21.3M | -13.8M |
| Depreciation and amortization | 663.0K | 662.9K | 663.0K | 663.2K | 1.11M | 1.28M | 1.68M | 1.43M | 1.68M | 1.82M |
| EBITDA | -15.8M | -466.2K | -17.2M | -21.3M | -29.9M | -7.68M | -4.52M | -9.32M | -19.6M | -12.0M |
| Interest expense | 29.6K | 26.9K | 1.08M | 1.24M | 1.66M | 1.51M | 1.51M | |||
| Income before tax | -13.6M | -838.0K | -15.6M | -21.5M | -31.9M | -6.68M | -4.14M | -6.94M | -19.3M | -4.79M |
| Income tax | -139.2K | -468.4K | -87.3K | -139.2K | -278.8K | -140.8K | -142.7K | -165.8K | -853.0K | 401.6K |
| Net income | -13.5M | -369.6K | -15.5M | -21.4M | -22.9M | -6.53M | -4.89M | -6.77M | -18.4M | -5.19M |
| Earnings per share, basic | -3.06 | -0.23 | -18.62 | -0.02 | -0.20 | -0.10 | -0.11 | -0.16 | -0.46 | -0.13 |
| Earnings per share, diluted | -3.06 | -0.23 | -18.62 | -0.02 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 19.9M | 14.2M | 12.6M | 12.1M | 33.6M | 21.4M | 3.15M | 9.79M | 18.3M | 32.9M |
| Short-term investments | 327.3K | 385.2K | 404.0K | 422.6K | ||||||
| Receivables | 813.4K | 11.9K | 126.9K | 426.1K | 6.78M | 192.9K | 40.7K | 621.0K | 523.5K | 7.60M |
| Inventory | 1 | 2 | 1 | 465.4K | 360.0K | 327.2K | ||||
| Current assets | 21.1M | 15.0M | 13.2M | 13.3M | 41.8M | 23.2M | 5.73M | 17.6M | 26.4M | 41.9M |
| Property, plant and equipment | 2.77K | 1.99K | 2.52K | |||||||
| Goodwill | 3.50M | 8.64M | 8.69M | 8.69M | 12.9M | 9.32M | 8.84M | 8.94M | 9.16M | 9.42M |
| Total assets | 28.7M | 28.6M | 27.6M | 28.6M | 65.3M | 40.8M | 23.7M | 37.6M | 47.8M | 64.6M |
| Accounts payable | 385.6K | 1.15M | 2.24M | 1.44M | 1.56M | 772.9K | 866.8K | 842.3K | 2.65M | 1.46M |
| Current liabilities | 756.6K | 4.22M | 3.83M | 2.74M | 3.36M | 1.77M | 5.68M | 9.67M | 9.76M | 10.7M |
| Total debt | 34.3K | 116.3K | 272.7K | 582.3K | 693.5K | 652.0K | 8.41M | 12.0M | 15.8M | 14.2M |
| Total liabilities | 4.11M | 9.59M | 10.2M | 6.55M | 8.40M | 5.01M | 15.0M | 25.2M | 35.3M | 33.5M |
| Shareholders' equity | 24.6M | 19.0M | 24.6M | 22.0M | 56.9M | 35.8M | 8.71M | 12.4M | 12.5M | 31.1M |
| Shares outstanding | 5.41M | 1.98M | 1.10M | 1.47B | 112.8M | 65.0M | 45.4M | 43.4M | 40.2M | 40.1M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.4M | 77.2K | -14.7M | -14.6M | -21.8M | -5.66M | -2.68M | -10.9M | -15.0M | -1.44M |
| Capital spending | -4 | 0 | 0 | -0 | -1.54K | -1.10K | -5.29K | -69.3K | -358.1K | -247.5K |
| Free cash flow | -12.4M | 77.2K | -14.7M | -9.85M | -21.8M | -5.67M | -2.69M | -11.0M | -15.4M | -1.69M |
| Cash from investing | 317.4K | 621.6K | -60.3K | -134.1K | 138.4K | 59.7K | 953.9K | |||
| Cash from financing | 17.9M | 1.53M | 15.1M | 3.86M | 27.0M | 23.7M | -3.68M | 3.05M | 1.94M | -2.08M |
| Share buybacks | -415.5K | -48.2K | -420.4K | |||||||
| Change in cash | 5.58M | 1.60M | 505.0K | -10.8M | 5.06M | 18.0M | -6.46M | -7.67M | -13.2M | -2.58M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 5, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Sep 18, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Sep 18, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 18, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Sep 18, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Jul 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 23, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | Feb 17, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 8-K · Current report | Dec 17, 2025 | Meeting outcome | SEC |
| DFAN14A | Dec 8, 2025 | Other filings | SEC |
| DFAN14A | Dec 8, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Dec 8, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Dec 4, 2025 | Meeting notice | SEC |
| DFAN14A | Dec 3, 2025 | Other filings | SEC |
| DFAN14A | Dec 2, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 2, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Dec 1, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 28, 2025 | Big-stake notice | SEC |
| DFAN14A | Nov 26, 2025 | Other filings | SEC |
| DFRN14A | Nov 25, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Nov 25, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Nov 24, 2025 | Meeting notice | SEC |
| DEFC14A | Nov 24, 2025 | Other filings | SEC |
| DEFC14A | Nov 24, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2025 | Big-stake notice | SEC |
| PREC14A | Nov 14, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Nov 12, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Nov 12, 2025 | Meeting notice | SEC |
| PREC14A | Nov 12, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 31, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 31, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 27, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 27, 2025 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 23, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 20, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| 10-K · Annual report | Sep 29, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Sep 23, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jul 29, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 18, 2025 | Current report | SEC |
| 8-K · Current report | May 20, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 20, 2025 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | May 19, 2025 | Insider trade | SEC |
| NT 10-Q · Late filing notice | May 15, 2025 | Explanation request | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | Feb 12, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 4, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 28, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jan 28, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 28, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 28, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jan 27, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 7, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jan 7, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 30, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| POS AM · Amendment to an effective registration | Dec 23, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Dec 23, 2024 | Offer document | SEC |
| 15-12G | Dec 23, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 8-K · Current report | Dec 12, 2024 | Meeting outcome | SEC |
| S-3/A · Registration statement, amended | Nov 25, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 21, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2024 | Material contract | SEC |
| S-3 · Registration statement | Nov 18, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Nov 13, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Current report | SEC |
| 8-K · Current report | Oct 10, 2024 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Oct 9, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2024 | Material contract | SEC |
| 10-K · Annual report | Sep 30, 2024 | Annual report | SEC |
| 8-K · Current report | Jul 16, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 8, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 27, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jun 26, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 24, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 21, 2024 | Other filings | SEC |
| F-1 · Registration statement | Jun 18, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jun 3, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 15, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Jan 18, 2024 | Other filings | SEC |
| 20-F/A · Annual report, amended | Jan 17, 2024 | Annual report | SEC |
| CORRESP · Letter to the SEC | Jan 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 8, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jan 4, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 30, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 30, 2023 | Big-stake notice | SEC |
| 20-F · Annual report | Oct 18, 2023 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Oct 16, 2023 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 10, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Sep 29, 2023 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Sep 29, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 31, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 28, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 25, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 24, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 7, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 7, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 3, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 15, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 11, 2023 | Other filings | SEC |
| F-3 · Registration statement | May 5, 2023 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Apr 27, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 9, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 23, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 23, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 21, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 30, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 18, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 9, 2023 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 19, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 16, 2022 | Current report | SEC |
| 424B4 · Prospectus | Nov 18, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 17, 2022 | Other filings | SEC |
| F-1MEF · Registration of more shares for the same offering | Nov 16, 2022 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2022 | Current report | SEC |
| CORRESP · Letter to the SEC | Nov 14, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 14, 2022 | Other filings | SEC |
| F-1/A · Registration statement, amended | Nov 14, 2022 | Offer document | SEC |
| F-1 · Registration statement | Nov 10, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 4, 2022 | Other filings | SEC |
| DRS · Draft registration statement | Oct 31, 2022 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 25, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 18, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 18, 2022 | Current report | SEC |
| 20-F · Annual report | Oct 14, 2022 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Oct 6, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 4, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 21, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 25, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 8, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 29, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 20, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 5, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 13, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 18, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 16, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 29, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 23, 2022 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 14, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jan 28, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 12, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 4, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 3, 2022 | Current report | SEC |
| SC 13D · Big-stake notice | Dec 30, 2021 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Dec 22, 2021 | Current report | SEC |
| S-8 · Registration statement for employee plans | Dec 20, 2021 | Offer document | SEC |
| 424B4 · Prospectus | Dec 17, 2021 | Offer document | SEC |
This page holds 200 of 421 filings. Open Filings
Cap table
Built by 6ix from Neuphoria Therapeutics Inc.’s releases · as of Sep 17, 2026
- Common shares
- 5,411,334
- Fully diluted
- 5,411,334
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 5,411,334 | Sep 17, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 17, 2026 | 5,411,334 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Spyros Papapetropoulos Other companies: Lipocine Inc. (Director · Since at least Apr 11, 2022); Vigil Neuroscience Inc (Chief Medical Officer · Jan 6, 2022 – Nov 18, 2022 · Past); Adamas Pharmaceuticals Inc (Director · Nov 22, 2020 – Nov 24, 2021 · Past) | President and CEO, Director · Since at least Jul 1, 2024 |
| Timothy M Cunningham Other companies: Rein Therapeutics, Inc. (See Remarks · May 16, 2024 – May 16, 2024 · Past); Alaunos Therapeutics, Inc. (interim CFO · Feb 17, 2021 – Feb 17, 2021 · Past); Organogenesis Holdings Inc. (Chief Financial Officer · Dec 10, 2018 – Apr 22, 2020 · Past) | Chief Financial Officer · Jul 1, 2024 – Jul 1, 2024 · Past |
| Aaron N. D. Weaver Other companies: Interactive Strength Inc. (Non-Employee Director · Since at least Apr 27, 2023) | Director · Jul 1, 2024 – Jul 1, 2024 · Past |
| Tim Cunningham Other companies: Rein Therapeutics, Inc. (Interim Chief Financial Officer · Since at least Nov 4, 2026) | Fractional CFO · Since at least Nov 4, 2026 |
| Alan Fisher | Non-Executive Chairman · Since at least Jul 1, 2024 |
| David Wilson | Non-Executive Director · Since at least Jul 1, 2024 |
| Jane Ryan | Non-Executive Director · Since at least Apr 16, 2025 |
| Miles Davies | Non-Executive Director · Since at least Dec 8, 2025 |
| Peter Miles Winston Davies | Director · Since at least Jul 1, 2024 |
| Spyridon Papapetropoulos | IR & PR · Since at least Dec 8, 2025 |
Log in to ask 6ix AI your own questions about Neuphoria Therapeutics Inc.